Remdesivir Rivals Hit Indian Market

Hetero And Cipla's Versions Launched, 'Surplus' Envisaged By August

 
• By Anju Ghangurde and Dave Wallace

Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.

Coins, money and COVID-19 on scale. Concepts of economics against coronavirus. Balancing and managing losses. 3D render
Hetero, Cipla Hit Market With Generic Remdesivir • Source: Shutterstock

More from Generics

More from Products